Company Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria.
Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 5, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Ms. Mina Kim |
Contact Details
Address: 4149 Liberty Canyon Rd. Agoura Hills, California 91301 United States | |
| Phone | 805-871-4300 |
| Website | acelyrin.com |
Stock Details
| Ticker Symbol | SLRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001962918 |
| CUSIP Number | 00445A100 |
| ISIN Number | US00445A1007 |
| Employer ID | 85-2406735 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shao-Lee Lin M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Gilbert M. Labrucherie J.D. | Chief Financial Officer, Principal Financial Officer and principal accounting officer |
| Mina Kim | Chief Legal and Administrative Officer |
| Tyler Marciniak | Head of Investor Relations and Communications |
| Ron Oyston | Chief People Officer |
| Dr. Paul M. Peloso M.D., M.Sc. | Chief Medical Officer |
| Suzy Buckhalter CPA | Senior Director of Finance and Accounting |
| Kenneth A. Lock | Chief Commercial Officer |
| Dr. Shephard Mpofu M.D. | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 28, 2024 | 8-K/A | [Amend] Current report |
| May 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 9, 2024 | 8-K | Current Report |
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |